扶正抗癌方联合吉非替尼治疗晚期肺腺癌疗效观察  

Clinical Observation of Fuzheng Kangai Prescription Combined with Gefitinib in Treating for Advanced Lung Adenocarcinoma

作　　者：杨亮亮[1] 庞瑞[1] YANG Liangliang;PANG Rui(The Affiliated Tumor Hospital to Xinjiang Medical University, Wrumqi Xinjiang China 83000)

机构地区：[1]新疆医科大学附属肿瘤医院,新疆乌鲁木齐830000

出　　处：《中医学报》2018年第5期706-708,共3页Acta Chinese Medicine

基　　金：新疆医科大学附属肿瘤医院科研启动基金(2014-14)

摘　　要：目的:观察扶正抗癌方联合吉非替尼治疗晚期肺腺癌的临床效果。方法:选取90例晚期肺腺癌患者作为研究对象,按随机数字表法分为对照组和试验组,每组45例。对照组采用吉非替尼治疗;试验组在对照组基础上加用扶正抗癌方治疗,观察治疗后两组患者临床疗效、T淋巴细胞水平、生存质量和不良反应。结果:治疗后对照组有效率为64.44%,试验组有效率为80.00%,两组比较,差异有统计学意义(P<0.05);治疗后试验组患者CD_3^+、CD_4^+、CD_8^+水平高于对照组,CD_4^+/CD_8^+水平低于对照组,两组比较,差异有统计学意义(P<0.05);生存质量方面,两组患者角色功能、社会功能、情绪功能、躯体功能比较,差异有统计学意义(P<0.05);两组患者白细胞减少、皮疹瘙痒、肝肾功能损害、恶心呕吐、腹泻不良发生率比较,差异有统计学意义(P<0.05)。结论:扶正抗癌方联合吉非替尼治疗晚期肺腺癌患者临床效果显著,可改善患者T淋巴细胞水平及生存质量,减少不良反应。Objective： To observe the clinical effects of Fuzheng Kang’ai Prescription and Gefitinib in treatment of advanced Lung adenocarcinoma in order to find the best treatment. Methods： Ninety patients with advanced lung adenocarcinoma were selected as study subjects and were randomly divided into two groups. 45 patients in the control group were treated with gefitinib and 45 patients in the experimental group were treated with Fuzheng Kangai Prescription in addition to that of the control group. The clinical efficacy,T lymphocyte levels,quality of life,and adverse reactions in both groups after treatment were observed. Results： After treatment,the effective rate in the control group was 64. 44%,and the effective rate in the experimental group was 80%. The difference between the two groups was statistically significant(P 〈 0. 05）. The levels of CD3＋,CD4＋,and CD8＋in the experimental group were significantly higher than those in the control group after treatment,and the level of CD4＋/CD8＋was significantly lower than that of the control group(P 〈 0. 05）. There was a statistically significant difference in the quality of life between the two groups in terms of social role and function,emotional function and physical function(P 〈 0. 05）. There was a statistically significant difference in the incidence of leukopenia,pruritus,liver and kidney dysfunction,nausea and vomiting,and diarrhea between the two groups(P 〈 0. 05）. Conclusion： Fuzheng Kang’ai Prescription combined with gefitinib has significant clinical effect on patients with advanced Lung adenocarcinoma,which can improve the level of T lymphocytes and patients’ quality of life as well as reducing the adverse reactions.

关 键 词：肺腺癌 肿瘤 扶正抗癌方 吉非替尼 T淋巴细胞亚群 生存质量 中医药治疗 中西医结合 

分 类 号：R273.42[医药卫生—中西医结合]